First name,Last name,Preferred title,Overview,Position,Department,Individual
John,Edwards,Professor,,Professor,Veterinary Pathobiology,https://scholars.library.tamu.edu/vivo/display/n09bbd732
Carolyn,Cannon,Associate Professor,"Our goal is to develop novel, non-toxic antimicrobial formualtions with efficacy against gram-positive and gram-negative multi-drug resistant pathogens.",Associate Professor,Microbial Pathogenesis and Immunology,https://scholars.library.tamu.edu/vivo/display/n0b3870aa
Jeffrey,Watkins,Professor,"My research is focused on improving patient outcomes in equine orthopedic disease in the clinical setting using spontaneous occurring disease in patients present to the large animal hospital. The majority of my work has centered on the management of end stage degenerative joint disease and long bone fractures. Specific areas of interest include conditions affecting the proximal interphalangeal joint and management of fractures of the humerus and femur using intramedullary, interlocking nail constructs.",Professor,Large Animal Clinical Sciences,https://scholars.library.tamu.edu/vivo/display/n0c7b8009
Lawrence,Wolinsky,Dean,,Dean||Professor||Faculty Fellow,Periodontics||School of Dentistry||Center for Health Systems and Design,https://scholars.library.tamu.edu/vivo/display/n0d0247f9
James,Sacchettini,Professor,"My lab uses X-ray crystallography to better understand the relationship between proteins and ligands. Tiny differences in the structure of a molecule can radically change the interaction between a protein and ligand and we are only begining to understand how many factors play a role in this interaction. By manipulating the individual components of a compound it is possible to create a chemical that binds to the protein better than the natural substrate, and prevent the natural reaction from occurring. This is the basis for rational drug design. Our efforts have lead us to collaborations with other labs and scientists in many disciplines as our approach to directed compound design has applications not only in basic research but also in pesticide development, health research and clinical research.",Professor,Biochemistry and Biophysics,https://scholars.library.tamu.edu/vivo/display/n90385563
Larry,Suva,Professor and Head,"The development, control and diseases of the musculoskeletal system have been my scholarly interests for the past 35+ years. Understanding how the musculoskeletal system adapts and progresses throughout life is the basis of my expertise. My research focus has been the skeletal consequences of disease, such as breast cancer bone metastasis and multiple myeloma, fracture healing, osteoporosis, and most recently rare bone diseases. Current research efforts include a focus on utilizing in vivo models (murine and large animals) to discover regulatory pathways fundamental to bone physiology and the development of rare bone disease preclinical model(s) that may provide novel insight into future therapeutic directions. A critical aspect of my academic philosophy is an open door policy and the importance of one-on-one interactions. We must strive to provide training and exposure for our students as they prepare for careers both in and out of academic medicine and research. I emphatically believe that these teaching and mentoring experiences have shaped my scientific career and have helped mold my teaching and mentoring philosophy of placing the best professional, academic, social and personal development of faculty, students and staff above all else.",Professor and Head,Veterinary Physiology and Pharmacology,https://scholars.library.tamu.edu/vivo/display/n98338eea
Karen,Snowden,Professor and Associate Department Head,"Parasites of public health importance, host-parasite interactions, development of animal models for the study of parasitologic diseases and treatments, and development of molecular and immunologic methods for parasitologic diagnosis.",Professor and Associate Department Head,Veterinary Pathobiology,https://scholars.library.tamu.edu/vivo/display/naab1ec85
Robert,Triplett,Clinical Professor,,Clinical Professor,Oral and Maxillofacial Surgery,https://scholars.library.tamu.edu/vivo/display/ncfb93a6c
Dekai,Zhang,Associate Professor,"Our laboratory is studying the molecular mechanisms of innate immune recognition by identification and analysis of receptors involved in innate immune recognition and activated signaling pathways. We are particularly interested in the recently identified family of Toll-like receptors, which play a critical role in the mounting of innate immune responses. We wish to understand the mechanisms by which TLRs recognize different pathogen associate molecular patterns (PAMPs), as well as the regulatory mechanisms of TLR signal pathways that lead to NF- k B activation. We are also interested in studying the important links between chronic infection, inflammation and cancer by utilizing biochemical as well as whole animal approaches.",Associate Professor||Associate Professor,Center for Infectious and Inflammatory Diseases||Institute of Biosciences and Technology,https://scholars.library.tamu.edu/vivo/display/ndf8a94d4
Darrell,Pilling,Research Assistant Professor,,Research Assistant Professor,Biology,https://scholars.library.tamu.edu/vivo/display/ne8a9ecc1
Jan,Suchodolski,Professor,"Our research is focused on gastrointestinal function testing, gastrointestinal pathogens, and intestinal microbial ecology with an emphasis on probiotics and prebiotics and how intestinal pathogens lead to disturbances in the intestinal microbiome of companion animals.",Associate Director of GI Lab||Professor,Small Animal Clinical Sciences||Small Animal Clinical Sciences,https://scholars.library.tamu.edu/vivo/display/nf0f36949
Noah,Cohen,Distinguished Professor and Associate Department Head,,Distinguished Professor and Associate Department Head,Large Animal Clinical Sciences,https://scholars.library.tamu.edu/vivo/display/nf22c59c1
Richard,Gomer,Distinguished Professor,"Our laboratory is working on three areas of biomedicine, trying to move observations from basic research into the clinic. First, we are studying how the sizes of tissues and tumors are regulated, and how this can be manipulated for therapeutic purposes. As a model system, we are using the simple eukaryote Dictyostelium discoideum, which allows us to combine techniques such as biochemistry, genetics, computer modeling, and cell biology to study tissue size regulation. We have found that a secreted protein as well as the unusual molecule polyphosphate are signals in negative feedback loops that inhibit Dictyostelium cell proliferation, and we are studying the signal transduction pathway to understand similar mechanisms in humans.
Second, we are studying how some secreted proteins can make cells move away from the source of the signal. We found such a signal (called a chemorepellent) in Dictyostelium, and then found a similar signal in humans. We are working to understand the signal transduction pathway for both. The human signal repels neutrophils, and we found that this can be used therapeutically in mouse models of neutrophil-driven diseases such as rheumatoid arthritis and acute respiratory distress syndrome.
Third, we have found that a human blood protein called Serum Amyloid P (SAP) regulates a key step in the formation of scar tissue as well as the formation of the scar-like lesions in fibrosing diseases such as congestive heart failure and pulmonary fibrosis. We are studying this mechanism, and a biotech company (Promedior, now sold to Roche) we co-founded is testing SAP as a therapy for fibrosis in patients in a Phase 3 trials.",Distinguished Professor,Biology,https://scholars.library.tamu.edu/vivo/display/nf41f3898
Joerg,Steiner,Professor,"My veterinary career has mainly focused on two aspects, patient care and clinically-relevant research. As a veterinary clinician and clinical teacher I am exposed to a wide variety of canine and feline patients with complex medical conditions. These patients serve as a constant source of new clinical problems that beckon to be studied further. Sometimes these studies are merely clinical, relating to characterization of an uncommon condition, diagnosis of a difficult-to-diagnose condition, or a novel therapeutic approach to a well-described condition. In other instances studies that are spurred by clinical cases are more basic-science based, utilizing state-of-the-art technologies to further evaluate the etiology or pathogenesis of a disease. In some instances, studies may provide comparative aspects related to experimental animals, such as rodents or primates, or even to human patients with similar conditions. I believe that my role as a mentor can be unique in that I can help graduate students bridge the gap between science and clinical aspects and between veterinary and human medical interests - giving us further opportunities to advance the concept of one-health.","Professor||Director, Gastrointestinal Laboratory",School of Veterinary Medicine and Biomedical Sciences||Small Animal Clinical Sciences,https://scholars.library.tamu.edu/vivo/display/nf4de66a0
Mansoor,Khan,Professor and Vice Dean,"Dr. Mansoor A. Khan serves as a professor and Vice Dean of the Texas A&M University Rangel College of Pharmacy at College Station, Texas. Prior to joining Texas A&M in 2015, he served as the Director of Product Quality Research and a Senior Biomedical Research Scientist (SBRS) at CDER in US Food and Drug Administration for over eleven years. In FDA, he led the research and review teams to promote manufacturing science, and served as a founding member of the FDA Emerging Technology Team. Dr. Khan received his Ph.D. degree in industrial pharmacy form St. Johns University in NY. He has published over 335 peer-reviewed manuscripts in pharmaceutical formulations and manufacturing sciences, and delivered over 300 presentations world-wide. Dr. Khan's research, currently supported by the NIH and FDA, spans drug delivery and formulations, and he has received over ten million dollars in funding as a principal investigator.
Dr. Khan has held leadership positions at the AAPS including elected chair of formulations design and development (FDD) section. He serves on the editorial board of Pharmaceutical Technology, International Journal of Pharmaceutics, AAPSPharmsciTech, and the Drug Delivery and Translational Research. He has received about 20 FDA/CDER review, research, and exemplary achievement awards, outstanding alumni award at St. Johns University College of Pharmacy, Excellence Award in Texas A&M University. He received the 2012 AAPS Research Achievement Award in Formulations Design and Development. He is also an AAPS and AAiPS Fellow. Dr. Khan served as FDA representative to the World Health Organization (WHO), United States Pharmacopoeia (USP), European Medicine Agency (EMA), DARPA, NIH, National Institute of Pharmaceutical Technology and Education (NIPTE), and International Pharmaceutical Federation (FIP). He is also a member of the European Union Academy of Sciences.",Regents Professor and Presidential Impact Fellow,Center for Microencapsulation and Drug Delivery,https://scholars.library.tamu.edu/vivo/display/nfc5f1cd6